80% Of Organ Transplants Between 1995 And 2021 Were On Men: Government Data

New Delhi: More than 80 per cent of the total 36,640 transplants from dead and living donors between 1995 and 2021 were performed on men, with the government saying it has taken several steps to address the gender disparity in the sphere. According to government data presented in Lok Sabha on Friday in a written response to a question, Minister of State for Health S P Singh Baghel said that of the total transplants, 29,695 were performed on men and 6,945 on women, which translates to a ratio of about 4:1.

However, the share of women receiving transplants increased from 27.6 per cent in 2019 to nearly 30 per cent in 2022.

The answer came in response to a question asked by YSR Congress Party MP Kuruva Gorantla Madhav. Madhav had asked if the government has taken cognisance of the fact that between 1995 and 2021, four out of five organ recipients have been men in the country and what are the steps taken to address the issue.

In his response, Baghel said the government has implemented the National Organ Transplant Programme under which steps have been taken to raise awareness on organ donation.

In order to narrow down the trend of gender disparity in organ transplants, the Ministry of Health has been conducting regular awareness and sensitisation sessions, he said.

Activities have been organised on various ethical aspects of organ donation and transplantation for different stakeholders such as state government representatives, legal representatives, police personnel, non-governmental organisations, healthcare professionals of Institutions/hospitals, etc.

Related Posts

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

The Team Meticulously averted the Risk of Thrombosis, Husband was Donor Delhi/NCR : Doctors at Yashoda Medicity have successfully performed a high-risk kidney transplant in a 28-year-old woman with Antiphospholipid…

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

Avacta, a UK-based clinical stage biotech, is differentiated clinical-stage oncology specialist, increasingly defined by continuing progress with its second-generation pre|CISION tumour-activated Peptide Drug Conjugate (PDC) platform. The lead Gen Two…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

Puresta launches EVERQ, AI-powered skin-health platform

Puresta launches EVERQ, AI-powered skin-health platform

Stem cell therapy for autism only in approved clinical trials: Centre

Stem cell therapy for autism only in approved clinical trials: Centre